Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Castle Biosciences is expected to report Q3 2026 results after market close on November 5. Analysts forecast a loss of $0.3544 per share and revenue of $92.41 million.
• The company exceeded expectations in its previous quarter, reporting a $0.07 per-share loss versus the projected $0.41 loss and revenue of $99.86 million versus the $86.23 million consensus.
• CSTL shares were up 6.3% and analysts maintain a “Moderate Buy” consensus, with an average price target of $42.00; however, insiders have sold about $6.98 million worth of stock over the past 90 days.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3544) per share and revenue of $92.41 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. On average, analysts expect Castle Biosciences to post ($1.29) EPS for the current fiscal year and ($0.93) EPS for the next fiscal year.

Castle Biosciences Trading Up 6.3%

CSTL opened at $36.68 on Thursday. The firm has a market cap of $1.12 billion, a P/E ratio of -55.58 and a beta of 0.94. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $34.01 and a 200 day moving average of $28.69.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CSTL shares. Wall Street Zen downgraded Castle Biosciences from a "buy" rating to a "hold" rating in a research report on Saturday, October 24th. BTIG Research lifted their target price on Castle Biosciences from $40.00 to $44.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Weiss Ratings raised Castle Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, July 31st. Finally, Robert W. Baird set a $36.00 target price on Castle Biosciences in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Castle Biosciences currently has an average rating of "Moderate Buy" and an average price target of $42.00.

Insider Buying and Selling at Castle Biosciences

In other news, insider Derek J. Maetzold sold 20,356 shares of the company's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $31.11, for a total transaction of $633,275.16. Following the transaction, the insider owned 21,479 shares of the company's stock, valued at approximately $668,211.69. This represents a 48.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen Oelschlager sold 12,384 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $34.42, for a total value of $426,257.28. Following the transaction, the chief operating officer directly owned 72,649 shares in the company, valued at approximately $2,500,578.58. This represents a 14.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 214,894 shares of company stock worth $6,976,395 over the last 90 days. Company insiders own 6.10% of the company's stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.